These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8619091)

  • 1. Rheumatoid arthritis. Outcome measures.
    Paulus HE; Bulpitt KJ
    Rheum Dis Clin North Am; 1995 Aug; 21(3):605-18. PubMed ID: 8619091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endpoints in rheumatoid arthritis.
    Tugwell P; Boers M; Baker P; Wells G; Snider J
    J Rheumatol Suppl; 1994 Oct; 42():2-8. PubMed ID: 7823314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
    Pincus T; Strand V; Koch G; Amara I; Crawford B; Wolfe F; Cohen S; Felson D
    Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.
    Tugwell P; Wells G; Strand V; Maetzel A; Bombardier C; Crawford B; Dorrier C; Thompson A
    Arthritis Rheum; 2000 Mar; 43(3):506-14. PubMed ID: 10728742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study.
    Anderson JJ; Bolognese JA; Felson DT
    Arthritis Rheum; 2003 Nov; 48(11):3031-8. PubMed ID: 14613263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measures of rheumatoid arthritis disease activity.
    Kirwan J
    J Rheumatol; 2009 Feb; 36(2):442-3; author reply 443-4. PubMed ID: 19208571
    [No Abstract]   [Full Text] [Related]  

  • 7. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis.
    Kosinski M; Zhao SZ; Dedhiya S; Osterhaus JT; Ware JE
    Arthritis Rheum; 2000 Jul; 43(7):1478-87. PubMed ID: 10902749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis.
    Harrison MJ; Tricker KJ; Davies L; Hassell A; Dawes P; Scott DL; Knight S; Davis M; Mulherin D; Symmons DP
    J Rheumatol; 2005 Dec; 32(12):2330-6. PubMed ID: 16331758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-driven outcomes in rheumatoid arthritis.
    Wells GA
    J Rheumatol Suppl; 2009 Jun; 82():33-8. PubMed ID: 19509328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study.
    Lehman AJ; Esdaile JM; Klinkhoff AV; Grant E; Fitzgerald A; Canvin J;
    Arthritis Rheum; 2005 May; 52(5):1360-70. PubMed ID: 15880810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
    Ogrendik M
    Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
    Mease PJ; Revicki DA; Szechinski J; Greenwald M; Kivitz A; Barile-Fabris L; Kalsi J; Eames J; Leirisalo-Repo M
    J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs--results of the British Rheumatoid Outcome Study Group randomized controlled clinical trial.
    Symmons D; Tricker K; Harrison M; Roberts C; Davis M; Dawes P; Hassell A; Knight S; Mulherin D; Scott DL;
    Rheumatology (Oxford); 2006 May; 45(5):558-65. PubMed ID: 16263778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Nijmegen inception cohort of early rheumatoid arthritis.
    Welsing PM; van Riel PL
    J Rheumatol Suppl; 2004 Mar; 69():14-21. PubMed ID: 15053447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials.
    Boers M; Tugwell P; Felson DT; van Riel PL; Kirwan JR; Edmonds JP; Smolen JS; Khaltaev N; Muirden KD
    J Rheumatol Suppl; 1994 Sep; 41():86-9. PubMed ID: 7799394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
    Sesin CA; Bingham CO
    Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
    Farahani P; Levine M; Gaebel K; Thabane L
    Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How should rheumatoid arthritis disease activity be measured today and in the future in clinical care?
    Sokka T
    Rheum Dis Clin North Am; 2010 May; 36(2):243-57. PubMed ID: 20510232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.